NEWS ON THE FIGHT FOR BETTER TREATMENT, A VACCINE, AND A CURE FOR AIDS
The Antiviral Report: A Critical Review of New Antiretroviral Drugs & Treatment Strategies
June 1998 - In January, 1996, at the Third Conference on Retroviruses and Opportunistic Infections in Washington, DC, I found myself standing amidst some very rude scientists with sharp elbows in a generic overcrowded conference hall, staring at the survival curves of patients treated with ritonavir in combination with nucleoside analogues, and I started crying. Over the course of the six month study, ritonavir-treated patients were surviving much more frequently than a similar group of participants who had been treated with a placebo and nucleoside analogues. AIDS research had finally paid off; effective therapy would be available for the hundreds of thousands of HIV-infected people in the United States, including some of those for whom I care most dearly.
Notes from the Gallo Lab Meeting
19 September 1998 - Late every August, the once-and-future greats (and some not-so greats) of AIDS research pay pilgrimage to HIV co-discoverer Robert C. Gallo at the annual laboratory meeting once, in palmier days, hosted in Bethesda by the NCI Laboratory of Tumor Cell Biology, now hosted by the Institute for Human Virology (IHV) and held at the tourist-friendly Hyatt Regency Harborside in glamorous, sweltering Baltimore, Maryland. Mark Harrington attended the first four days of the week- long research gab-fest.
AIDS Related Opportunistic Infections Report, 1998
February 1998 - This OI report attempts to detail what we know and what we don’t know about the epidemiology, pathogenesis, diagnosis, treatment and prevention of approximately sixteen viral, bacterial, fungal and protozoal infections. The OI Report, version 2.0, is the work of eight dedicated members of TAG’s OI Committee who have spent over two years researching, writing and editing articles on their respective pathogens. All of us were gifted to have prominent AIDS researchers -- many of whom conducted major OI studies detailed in the report -- as our advisors and editors.